Macroprolactinomas

Nearly 20% of women with a macroprolactinoma experienced symptomatic tumor progression during pregnancy, suggesting that continued dopamine receptor agonist therapy during pregnancy may be warranted, according to findings from a retrospective study published in Clinical Endocrinology.